ITPC report issues guidance on 2010 WHO ARV targets

3 December 2007

The International Treatment Preparedness Coalition, a 1,000 strong group of HIV/AIDS patients and activists from more than 125 countries, says that while the scale up of HIV treatment services is having a beneficial effect, high drug prices as well as patent and registration barriers are hindering progress. The conclusion, detailed in the ITPC's report, Missing the Target 5: Improving AIDS Drug Access and Advancing Health Care for All, is based on the organization's analysis of the current state of drug provision in 14 countries.

ITPC project coordinator Gregg Gonsalves said that "the foundations to make the 2010 target are in place in many countries," and added that, "if governments, global agencies and drug companies focus on tactically improving AIDS drug access by continually lowering costs, ending patent and regulatory problems and fixing drug availability logistics, while simultaneously strengthening health systems, there is real possibility for making the 'near universal access' target by 2010." The report goes on to make a list of country specific recommendations, and provide guidance for governments and global agencies, including:

- that the World Health Organization leads efforts to inform countries and health care providers about changes to first- and second-line treatment regimens;

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight